Correction: Zanella et al. Tenofovir, Another Inexpensive, Well Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection. Pharmaceuticals 2021, 14, 454

Zanella, Isabella; Zizioli, Daniela; Castelli, Francesco; Quiros-Roldan, Eugenia

doi:10.3390/ph14080827

Open AccessCorrection

Correction: Zanella et al. Tenofovir, Another Inexpensive, Well Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection. Pharmaceuticals 2021, 14, 454

¹

Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy

²

Clinical Chemistry Laboratory, Cytogenetics and Molecular Genetics Section, Diagnostic Department, ASST Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy

³

University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy

^*

Author to whom correspondence should be addressed.

Pharmaceuticals 2021, 14(8), 827; https://doi.org/10.3390/ph14080827

Submission received: 16 July 2021 / Accepted: 5 August 2021 / Published: 23 August 2021

(This article belongs to the Special Issue COVID-19 in Pharmaceuticals)

Download Versions Notes

Text Correction

There was an error in the original article [1]. In the Abstract, page 1, line 12 from the top, the sentence “… remdesivir, a nucleotide analog that acts as reverse-transcriptase inhibitor, …” is incorrect.

A correction has been made to the Abstract.

The incorrect sentence must be replaced with “… remdesivir, a nucleotide analog that acts as RNA-dependent RNA-polymerase inhibitor, …”.

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.

Reference

Zanella, I.; Zizioli, D.; Castelli, F.; Quiros-Roldan, E. Tenofovir, another inexpensive, well-known and widely available old drug repurposed for SARS-COV-2 infection. Pharmaceuticals 2021, 14, 454. [Google Scholar] [CrossRef]

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Share and Cite

MDPI and ACS Style

Zanella, I.; Zizioli, D.; Castelli, F.; Quiros-Roldan, E. Correction: Zanella et al. Tenofovir, Another Inexpensive, Well Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection. Pharmaceuticals 2021, 14, 454. Pharmaceuticals 2021, 14, 827. https://doi.org/10.3390/ph14080827

AMA Style

Zanella I, Zizioli D, Castelli F, Quiros-Roldan E. Correction: Zanella et al. Tenofovir, Another Inexpensive, Well Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection. Pharmaceuticals 2021, 14, 454. Pharmaceuticals. 2021; 14(8):827. https://doi.org/10.3390/ph14080827

Chicago/Turabian Style

Zanella, Isabella, Daniela Zizioli, Francesco Castelli, and Eugenia Quiros-Roldan. 2021. "Correction: Zanella et al. Tenofovir, Another Inexpensive, Well Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection. Pharmaceuticals 2021, 14, 454" Pharmaceuticals 14, no. 8: 827. https://doi.org/10.3390/ph14080827

APA Style

Zanella, I., Zizioli, D., Castelli, F., & Quiros-Roldan, E. (2021). Correction: Zanella et al. Tenofovir, Another Inexpensive, Well Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection. Pharmaceuticals 2021, 14, 454. Pharmaceuticals, 14(8), 827. https://doi.org/10.3390/ph14080827

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Correction: Zanella et al. Tenofovir, Another Inexpensive, Well Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection. Pharmaceuticals 2021, 14, 454

Reference

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI